Aricept and Neoplasm progression - a phase IV clinical study of FDA data

Summary:

Neoplasm progression is reported as a side effect among people who take Aricept (donepezil hydrochloride), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Ibrance, and have Breast cancer female.

The phase IV clinical study analyzes which people have Neoplasm progression when taking Aricept. It is created by eHealthMe based on reports of 23,732 people who have side effects when taking Aricept from the FDA, and is updated regularly.

What is Aricept?

Aricept has active ingredients of donepezil hydrochloride. It is often used in alzheimer's disease. eHealthMe is studying from 24,756 Aricept users. Check the latest studies of Aricept.

What is Neoplasm progression?

Neoplasm progression (growth of tumour) is found to be associated with 1,068 drugs and 914 conditions by eHealthMe. Check the latest studies of Neoplasm progression.

On Jul, 27, 2026

23,732 people reported to have side effects when taking Aricept.
Among them, 22 people (0.09%) have Neoplasm progression.

Could Aricept cause Neoplasm progression?

Among these 22 people:

How long have people been on Aricept when they have Neoplasm progression? *

What is the gender of people who have Neoplasm progression when taking Aricept? *

female: 40.91 %
male: 59.09 %

What is the age of people who have Neoplasm progression when taking Aricept? *

What are other drugs people take besides Aricept? *

What are other side effects people have besides Neoplasm progression? *

Diarrhea: 8 people, 36.36%
Fatigue (feeling of tiredness): 7 people, 31.82%
Nausea (feeling of having an urge to vomit): 6 people, 27.27%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 6 people, 27.27%
Weight Decreased: 4 people, 18.18%
Oral Candidiasis (fungal infection of mouth): 3 people, 13.64%
Pneumonia: 3 people, 13.64%
Rashes (redness): 3 people, 13.64%
Depression: 3 people, 13.64%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 13.64%

What are the existing conditions these people have? *

Breast Cancer Female: 6 people, 27.27%
Metastatic Renal Cell Carcinoma (spreadable kidney cell tumour): 3 people, 13.64%
Renal Cell Carcinoma (a kidney cancer): 3 people, 13.64%
Lung Neoplasm Malignant (cancer tumour of lung): 2 people, 9.09%
Neoplasm Malignant (cancer tumour): 2 people, 9.09%
Multiple Myeloma (cancer of the plasma cells): 2 people, 9.09%
Gastric Cancer (stomach cancer): 1 person, 4.55%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 4.55%
Cardiac Failure: 1 person, 4.55%
Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Aricept and have Neoplasm progression?

- Check whether Neoplasm progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Aricept:

Aricept (24,756 reports)

Browse all side effects of Aricept:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm progression:

Neoplasm progression (1,068 drugs)

Browse all the conditions that are associated with Neoplasm progression:

Neoplasm progression (914 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on donepezil hydrochloride (the active ingredients of Aricept) and Aricept (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.